Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AME Study of Poziotinib in Healthy Males
NCT04436562Phase 1Completed
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- May 2020
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of poziotinib in non-small cell lung cancer (NSCLC), sponsored by Spectrum Pharmaceuticals, Inc. Primary endpoints: Maximum Observed Plasma Concentration, Time to Attain Maximum Observed Plasma Concentration and 15 more. Started May 2020; status: completed.
02
Drugs
poziotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04436562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04436562.